Abstract
BackgroundInfliximab is a therapeutic monoclonal antibody that specifically targets Tumor Necrosis Factor alpha. In December 2004, the FDA conveyed an important drug warning on infliximab potential hepatotoxicity[1]. Several serious hepatic...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
